San Jose, California, June 29, 2021 (Global News Agency)-BGI Gene Americas, a global leader in diagnostic testing, today announced a partnership with Pennsylvania-based biotechnology company Advaite and the launch of dxpartnerships.com, A center for diagnostic companies seeking partnerships through licensing, original equipment manufacturer (OEM) or distribution agreements.
The partnership will add Advaite’s RapCov™ Rapid COVID-19 Test to BGI’s growing portfolio of diagnostic testing solutions. The Advaite test is a CLIA-exempt lateral flow immunoassay for the qualitative detection of immunoglobulin G (IgG) antibodies against the SARS-CoV-2 virus in whole blood samples from human fingertips. The RapCov™ rapid COVID-19 test is one of the first U.S.-made instant serological tests granted emergency use authorization by the U.S. Food and Drug Administration. It is simple to use and provides highly accurate results within 15 minutes, eliminating the need to send samples. Requirements to the laboratory. This partnership enables BGI to combine Advaite’s proprietary handheld test with its real-time fluorescent RT-PCR kit for SARS-CoV-2 detection, providing a central laboratory and point-of-care CLIA for hospital systems and other medical institutions Exemption testing solutions.
Advaite CEO Karthik Musunuri said: “Our rapid antibody test kit provides an ideal solution for screening large numbers of people and helps patients determine whether they have ever contracted this disease without their knowledge.” BGI’s collaboration to provide hospitals and other medical institutions with our innovative tests is easy in helping fight this ongoing epidemic.”
The COVID-19 pandemic has highlighted the global demand for the manufacture and distribution of accessible and accurate diagnostic test equipment. BGI’s launch of dxpartnerships.com enables the company to collaborate with a wide range of organizations in the field of diagnostic testing to advance diagnostic solutions. With mature business expertise and mature global footprint, working with BGI enables organizations to quickly and effectively commercialize their in vitro diagnostic solutions.
“As one of the world’s largest suppliers of COVID-19 detection reagents and automated systems, we are excited to work with Advaite to bring their pioneering detection solutions to the market and help stop the spread of the deadly coronavirus,” said Craig Hoechstetter , BGI’s corporate development. “Quick and easy testing can not only remind individuals whether they are infected, but also allow them to get treatment faster and take necessary measures to minimize the spread of the virus to colleagues, friends and family members, and ultimately save lives. By providing end-to-end With advanced high-quality molecular and serological testing, we provide a collaborative solution to respond to this epidemic by being one step ahead of the virus.”
To cooperate with BGI, please visit dxpartnerships.com. For more information on BGI and RapCov™ rapid COVID-19 testing, please visit bgi.com/us.
BGI Americas Corporation is a leading genomics and proteomics service provider in the Americas, affiliated to BGI Genomics, a listed company listed on the Shenzhen Stock Exchange. Founded in 2010, BGI Americas has grown to include businesses in Boston and San Jose, providing services to a wide range of customers in the fields of genetics research, drug development, and diagnostics. In response to the 2020 COVID-19 pandemic, BGI America introduced its diagnostic solutions to the North and South American markets and launched the in vitro diagnostic business. BGI brings 20 years of genomics experience to its customers and collaborators. We are committed to advancing genetic research, technology and application for the benefit of mankind.
ADVAITE Inc. is a biotechnology company headquartered in Malvern, Pennsylvania, focusing on developing new treatments and diagnostics to help patients suffering from various debilitating diseases. The word “Advaite” means “nothing”, unparalleled or unique. At ADVAITE, our team is eager to do this.
Currently, ADVAITE Inc. is focusing on developing new instant detection methods to help fight COVID-19, the most deadly disease in the modern world. ADVAITE has a highly complex CLIA laboratory in Chicago, Illinois, and an expanded state-of-the-art R&D facility in Malvern, Pennsylvania. ADVAITE continues to innovate, develop and commercialize first-class point-of-care testing to respond to this epidemic and help Affect a large number of people.
The ADVAITE RapCov™ rapid COVID-19 test is a lateral flow immunochromatographic test for the qualitative detection of IgG antibodies against SARS-CoV-2 in whole blood samples from human fingertips. The testing of fingertip whole blood samples is limited to CLIA-accredited laboratories that meet the requirements to perform high, medium, or exempt complexity testing. The test of fingertip whole blood samples is authorized to be used in POC, that is, in a patient care environment that operates in accordance with CLIA exemption certificates, compliance certificates, or certification certificates. At present, it is not clear how long the antibodies will last after infection, and whether the presence of antibodies will bring about protective immunity.
Post time: Jul-01-2021